Artal Group S.A. Amicus Therapeutics, Inc. Call Options Transaction History

Artal Group S.A.

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q4 2023 Feb 09, 2024	BUY	$9.97 - $14.52 $19.9 Million - $29 Million	2,000,000 Added 400.0%	2,500,000 $35.5 Million
Q2 2023 Aug 11, 2023	BUY	$10.72 - $13.3 $5.36 Million - $6.65 Million	500,000 New	500,000 $6.28 Million
Q1 2020 May 14, 2020	BUY	$6.63 - $11.16 $3.32 Million - $5.58 Million	500,000 Added 100.0%	1,000,000 $9.24 Million
Q4 2018 Feb 11, 2019	SELL	$8.38 - $13.44 $4.19 Million - $6.72 Million	-500,000 Reduced 50.0%	500,000 $4.79 Million
Q3 2018 Nov 09, 2018	BUY	$11.6 - $16.54 $5.8 Million - $8.27 Million	500,000 Added 100.0%	1,000,000 $12.1 Million
Q2 2018 Aug 10, 2018	SELL	$13.13 - $17.09 $5.25 Million - $6.84 Million	-400,000 Reduced 44.44%	500,000 $7.81 Million
Q1 2018 May 10, 2018	SELL	$13.76 - $17.12 $6.88 Million - $8.56 Million	-500,000 Reduced 35.71%	900,000 $13.5 Million
Q4 2017 Feb 09, 2018	BUY	$12.51 - $16.24 $5 Million - $6.5 Million	400,000 Added 40.0%	1,400,000 $20.1 Million
Q3 2017 Nov 08, 2017	BUY	$11.74 - $15.78 $11.7 Million - $15.8 Million	1,000,000	1,000,000 $15.1 Million

312

311M

467K

515K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.55B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.